COVID-19 induced pneumonia. COVID-19 causes the most severe form of pulmonary inflammation – bilateral interstitial pneumonia. In severe forms of this disease, ARDS (acute respiratory distress syndrome) develops, a secondary bacterial infection occurs, sepsis develops, and the risks of death increase significantly.

In Covid pneumonia, the destruction of epithelial cells both in the bronchi and in the capillaries plays a key role, as a result of which parenteral and oral drug delivery does not provide the desired therapeutic result. It should also be borne in mind that severe forms develop in comorbid patients, with already existing airway damage in the form of bronchospasm, bronchial obstruction and the decreased elasticity of the lung tissue.

All existing inhalers deliver aerosol into the airways regardless of the respiratory function and airway patency, therefore 25% -65% of the dose of the drug is deposited in the upper airways or on the endotracheal tube not reaching the inflammation focus.

PM&HM inhalers generate an aerosol that does not deposit in the upper respiratory tract but reaches the affected parts of the lungs. The aerosol itself is delivered only immediately before the patient inhales. The efficiency of drug delivery with this approach is expected to increase significantly. On the other hand, PM&HM inhalers can work with different types of drugs for pneumonia, including COVID-19 induced, antibacterial, antiviral, bronchospasm relieving drugs, mucolytics. Moreover, for each of these drugs, its own optimal parameters of aerosol generation have been determined, which ensure maximum delivery efficiency.

In cases when the patient's respiratory function is extremely weakened, and the drugs must be delivered sequentially, a critical factor for the treatment efficacy is the time interval of introducing an antibiotic into the affected parts of the lungs. Proceeding from the fact that this time interval will be rather short, the digital control of drug administration will allow tracking the time of administration, the sequence of drug use and the dose to be delivered to the lungs.
Thus, PM&HM inhalers:
VivoSpiro inhaler compatible drugs, as per laboratory tests:
  1. Levofloxacin
  2. Amikacin
  3. Tobramycin
  4. Gentamicin
  5. Budesonide
  6. Salbutamol
  7. Tiotropium bromide
  8. Ipratropium bromide
  9. Formoterol
  10. Beclometasone
  11. Acetylcysteine
  12. Ambroxol
Deliver the required dose of the drug to the affected area of the lungs.
Apply a treatment regimen with antibiotics, bronchodilators and mucolytics.
Provide control and recording of the treatment process for each patient.